{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:07:27Z","timestamp":1793506047081,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005366","name":"University of Oslo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005366","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s11060-026-05481-y","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T08:29:40Z","timestamp":1771921780000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Extent of resection and perioperative neurological status as prognostic markers in glioblastoma: a population-based study"],"prefix":"10.1007","volume":"177","author":[{"given":"Eduardo Erasmo","family":"Mendoza Mireles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne","family":"Blakstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Server","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Leske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erlend","family":"Skaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads","family":"Aarhus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petter","family":"Brandal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirik","family":"Helseth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e5l Andr\u00e8","family":"R\u00f8nning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar O.","family":"Vik-Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"5481_CR1","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/s41571-022-00623-3","volume":"19","author":"M Weller","year":"2022","unstructured":"Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, Bendszus M, Balana C, Chinot O, Dirven L, French P, Hegi ME, Jakola AS, Platten M, Roth P, Rud\u00e0 R, Short S, Smits M, Taphoorn MJB, von Deimling A, Westphal M, Soffietti R, Reifenberger G, Wick W (2022) EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood (vol 18, pg 170, 2021). Nat Rev Clin Oncol 19:357\u2013358. https:\/\/doi.org\/10.1038\/s41571-022-00623-3","journal-title":"Nat Rev Clin Oncol"},{"key":"5481_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. NEJM Evid 352:987\u2013996. https:\/\/doi.org\/10.1056\/NEJMoa043330","journal-title":"NEJM Evid"},{"key":"5481_CR3","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1093\/nop\/npad037","volume":"10","author":"EE Mendoza Mireles","year":"2023","unstructured":"Mendoza Mireles EE, Skaga E, Server A, Leske H, Brandal P, Helseth E, R\u00f8nning PA, Vik-Mo EO (2023) The benefit of complete resection of contrast enhancing tumor in glioblastoma patients: a population-based study. Neurooncol Pract 10:555\u2013564. https:\/\/doi.org\/10.1093\/nop\/npad037","journal-title":"Neurooncol Pract"},{"key":"5481_CR4","doi-asserted-by":"publisher","unstructured":"Price M, Ballard C, Benedetti J, Neff C, Cioffi G, Waite KA, Kruchko C, Barnholtz-Sloan JS, Ostrom QT (2024) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2017-2021. Neuro Oncol 26:vi1\u201385. https:\/\/doi.org\/10.1093\/neuonc\/noae145","DOI":"10.1093\/neuonc\/noae145"},{"key":"5481_CR5","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/neuonc\/now208","volume":"19","author":"H Gittleman","year":"2016","unstructured":"Gittleman H, Lim D, Kattan MW, Chakravarti A, Gilbert MR, Lassman AB, Lo SS, Machtay M, Sloan AE, Sulman EP, Tian D, Vogelbaum MA, Wang TJC, Penas-Prado M, Youssef E, Blumenthal DT, Zhang P, Mehta MP, Barnholtz-Sloan JS (2016) An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG oncology RTOG, 0525 and 0825. Neuro-Oncol 19:669\u2013677. https:\/\/doi.org\/10.1093\/neuonc\/now208","journal-title":"Neuro-Oncology"},{"key":"5481_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(07)70384-4","volume":"9","author":"T Gorlia","year":"2008","unstructured":"Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, Lacombe D, Stupp R (2008) Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981\/CE.3. Lancet Oncol 9:29\u201338. https:\/\/doi.org\/10.1016\/S1470-2045(07)70384-4","journal-title":"Lancet Oncol"},{"key":"5481_CR7","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3171\/jns.2001.95.2.0190","volume":"95","author":"M Lacroix","year":"2001","unstructured":"Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:190\u2013198. https:\/\/doi.org\/10.3171\/jns.2001.95.2.0190","journal-title":"J Neurosurg"},{"key":"5481_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3171\/2011.2.JNS10998","volume":"115","author":"N Sanai","year":"2011","unstructured":"Sanai N, Polley M-Y, McDermott MW, Parsa AT, Berger MS (2011) An extent of resection threshold for newly diagnosed glioblastomas: clinical article. J Neurosurg 115:3\u20138. https:\/\/doi.org\/10.3171\/2011.2.JNS10998","journal-title":"J Neurosurg"},{"key":"5481_CR9","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.3390\/cancers14133161","volume":"14","author":"NF Brown","year":"2022","unstructured":"Brown NF, Ottaviani D, Tazare J, Gregson J, Kitchen N, Brandner S, Fersht N, Mulholland P (2022) Survival outcomes and prognostic factors in glioblastoma. Cancers 14:3161","journal-title":"Cancers"},{"key":"5481_CR10","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamaoncol.2019.6143","volume":"6","author":"AM Molinaro","year":"2020","unstructured":"Molinaro AM, Hervey-Jumper S, Morshed RA, Young J, Han SJ, Chunduru P, Zhang Y, Phillips JJ, Shai A, Lafontaine M, Crane J, Chandra A, Flanigan P, Jahangiri A, Cioffi G, Ostrom Q, Anderson JE, Badve C, Barnholtz-Sloan J, Sloan AE, Erickson BJ, Decker PA, Kosel ML, LaChance D, Eckel-Passow J, Jenkins R, Villanueva-Meyer J, Rice T, Wrensch M, Wiencke JK, Oberheim Bush NA, Taylor J, Butowski N, Prados M, Clarke J, Chang S, Chang E, Aghi M, Theodosopoulos P, McDermott M et al. (2020) Association of maximal extent of resection of contrast-enhanced and non-contrast-enhanced tumor with survival within Molecular subgroups of patients with newly diagnosed glioblastoma. JAMA Oncol 6:495\u2013503. https:\/\/doi.org\/10.1001\/jamaoncol.2019.6143","journal-title":"JAMA Oncol"},{"key":"5481_CR11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3171\/2016.7.JNS16396","volume":"127","author":"M Rahman","year":"2017","unstructured":"Rahman M, Abbatematteo J, De Leo EK, Kubilis PS, Vaziri S, Bova F, Sayour E, Mitchell D, Quinones-Hinojosa A (2017) The effects of new or worsened postoperative neurological deficits on survival of patients with glioblastoma. J Neurosurg 127:123\u2013131. https:\/\/doi.org\/10.3171\/2016.7.JNS16396","journal-title":"J Neurosurg"},{"key":"5481_CR12","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3390\/brainsci12050544","volume":"12","author":"AF Haddad","year":"2022","unstructured":"Haddad AF, Young JS, Morshed RA, Berger MS (2022) Flairectomy: resecting beyond the contrast margin for glioblastoma. Brain Sci 12:544","journal-title":"Brain Sci"},{"key":"5481_CR13","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1093\/neuonc\/noac193","volume":"25","author":"P Karschnia","year":"2023","unstructured":"Karschnia P, Young JS, Dono A, H\u00e4ni L, Sciortino T, Bruno F, Juenger ST, Teske N, Morshed RA, Haddad AF, Zhang Y, Stoecklein S, Weller M, Vogelbaum MA, Beck J, Tandon N, Hervey-Jumper S, Molinaro AM, Rud\u00e0 R, Bello L, Schnell O, Esquenazi Y, Ruge MI, Grau SJ, Berger MS, Chang SM, van den Bent M, Tonn JC (2023) Prognostic validation of a new classification system for extent of resection in glioblastoma: a report of the RANO resect group. Neuro Oncol 25:940\u2013954. https:\/\/doi.org\/10.1093\/neuonc\/noac193","journal-title":"Neuro Oncol"},{"key":"5481_CR14","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3171\/2011.3.JNS10495","volume":"115","author":"O Marina","year":"2011","unstructured":"Marina O, Suh JH, Reddy CA, Barnett GH, Vogelbaum MA, Peereboom DM, Stevens GHJ, Elinzano H, Chao ST (2011) Treatment outcomes for patients with glioblastoma multiforme and a low Karnofsky performance scale score on presentation to a tertiary care institution: clinical article. J Neurosurg 115:220\u2013229. https:\/\/doi.org\/10.3171\/2011.3.JNS10495","journal-title":"J Neurosurg"},{"key":"5481_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.14791\/btrt.2018.6.e1","volume":"6","author":"J Lee","year":"2018","unstructured":"Lee J, Park SH, Kim YZ (2018) Prognostic evaluation of neurological assessment of the neuro-oncology scale in glioblastoma patients. Brain Tumor Res Treat 6:22\u201330. https:\/\/doi.org\/10.14791\/btrt.2018.6.e1","journal-title":"Brain Tumor Res Treat"},{"key":"5481_CR16","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/neuonc\/nox029","volume":"19","author":"L Nayak","year":"2017","unstructured":"Nayak L, DeAngelis LM, Brandes AA, Peereboom DM, Galanis E, Lin NU, Soffietti R, Macdonald DR, Chamberlain M, Perry J, Jaeckle K, Mehta M, Stupp R, Muzikansky A, Pentsova E, Cloughesy T, Iwamoto FM, Tonn J-C, Vogelbaum MA, Wen PY, van den Bent MJ, Reardon DA (2017) The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. Neuro-Oncology 19:625\u2013635. https:\/\/doi.org\/10.1093\/neuonc\/nox029","journal-title":"Neuro-Oncology"},{"key":"5481_CR17","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s11060-025-05218-3","volume":"175","author":"CB Trewin-Nybr\u00e5ten","year":"2025","unstructured":"Trewin-Nybr\u00e5ten CB, Lambert PC, Marienhagen K, Andreassen L, Johannesen TB, Niehusmann P, Oltedal L, Schipmann S, Skjulsvik AJ, Solheim O (2025) Unveiling regional differences in glioblastoma patient survival with real-world data from the Norwegian brain tumor quality registry. J Neurooncol 175:1355\u20131366","journal-title":"J Neurooncol"},{"key":"5481_CR18","unstructured":"SSB. Statistics Norway. https:\/\/www.ssb.no\/en\/statbank\/table\/07459\/. Accessed 31 Jan 2025"},{"key":"5481_CR19","doi-asserted-by":"publisher","first-page":"936","DOI":"10.21037\/apm-20-856","volume":"10","author":"C Wujanto","year":"2020","unstructured":"Wujanto C, Vellayappan B, Chang EL, Chao ST, Sahgal A, Lo SS (2020) Radiotherapy to the brain: what are the consequences of this age-old treatment? Ann Palliat Med 10:936\u2013952","journal-title":"Ann Palliat Med"},{"key":"5481_CR20","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s11060-024-04709-z","volume":"169","author":"H Blakstad","year":"2024","unstructured":"Blakstad H, Mendoza Mireles EE, Kierulf-Vieira KS, Singireddy D, Mdala I, Heggeb\u00f8 LC, Magelssen H, Sprauten M, Johannesen TB, Leske H (2024) The impact of cancer patient pathway on timing of radiotherapy and survival: a cohort study in glioblastoma patients. J Neurooncol 169:137\u2013145","journal-title":"J Neurooncol"},{"key":"5481_CR21","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/neuonc\/noad160","volume":"26","author":"P Karschnia","year":"2023","unstructured":"Karschnia P, Dietrich J, Bruno F, Dono A, Juenger ST, Teske N, Young JS, Sciortino T, H\u00e4ni L, van den Bent M, Weller M, Vogelbaum MA, Morshed RA, Haddad AF, Molinaro AM, Tandon N, Beck J, Schnell O, Bello L, Hervey-Jumper S, Thon N, Grau SJ, Esquenazi Y, Rud\u00e0 R, Chang SM, Berger MS, Cahill DP, Tonn J-C (2023) Surgical management and outcome of newly diagnosed glioblastoma without contrast enhancement (low-grade appearance): a report of the RANO resect group. Neuro-Oncol 26:166\u2013177. https:\/\/doi.org\/10.1093\/neuonc\/noad160","journal-title":"Neuro-Oncology"},{"key":"5481_CR22","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1097\/00006123-199805000-00054","volume":"42","author":"R Sawaya","year":"1998","unstructured":"Sawaya R, Hammoud M, Schoppa D, Hess KR, Wu SZ, Shi W-M, Wildrick DM (1998) Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery 42:1044\u20131055","journal-title":"Neurosurgery"},{"key":"5481_CR23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/nrneurol.2009.197","volume":"6","author":"M Weller","year":"2010","unstructured":"Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W, Hegi ME (2010) MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 6:39\u201351. https:\/\/doi.org\/10.1038\/nrneurol.2009.197","journal-title":"Nat Rev Neurol"},{"key":"5481_CR24","doi-asserted-by":"publisher","first-page":"977","DOI":"10.3171\/2015.5.JNS142087","volume":"124","author":"YM Li","year":"2016","unstructured":"Li YM, Suki D, Hess K, Sawaya R (2016) The influence of maximum safe resection of glioblastoma on survival in 1229 patients: can we do better than gross-total resection? J Neurosurg 124:977\u2013988. https:\/\/doi.org\/10.3171\/2015.5.JNS142087","journal-title":"J Neurosurg"},{"key":"5481_CR25","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3171\/2022.3.JNS212399","volume":"138","author":"L Di","year":"2023","unstructured":"Di L, Shah AH, Mahavadi A, Eichberg DG, Reddy R, Sanjurjo AD, Morell AA, Lu VM, Ampie L, Luther EM, Komotar RJ, Ivan ME (2023) Radical supramaximal resection for newly diagnosed left-sided eloquent glioblastoma: safety and improved survival over gross-total resection. J Educ Chang Neurosurg 138:62\u201369. https:\/\/doi.org\/10.3171\/2022.3.JNS212399","journal-title":"J Educ Chang Neurosurg"},{"key":"5481_CR26","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s11060-020-03541-5","volume":"148","author":"AH Shah","year":"2020","unstructured":"Shah AH, Mahavadi A, Di L, Sanjurjo A, Eichberg DG, Borowy V, Figueroa J, Luther E, de la Fuente MI, Semonche A, Ivan ME, Komotar RJ (2020) Survival benefit of lobectomy for glioblastoma: moving towards radical supramaximal resection. J Neurooncol 148:501\u2013508. https:\/\/doi.org\/10.1007\/s11060-020-03541-5","journal-title":"J Neurooncol"},{"key":"5481_CR27","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s11060-025-04950-0","volume":"172","author":"J Wach","year":"2025","unstructured":"Wach J, Vychopen M, G\u00fcresir E (2025) Prognostic revalidation of RANO categories for extent of resection in glioblastoma: a reconstruction of individual patient data. J Neurooncol 172:515\u2013525. https:\/\/doi.org\/10.1007\/s11060-025-04950-0","journal-title":"J Neurooncol"},{"key":"5481_CR28","doi-asserted-by":"publisher","unstructured":"Bjorland LS, Mahesparan R, Fluge \u00d8, Gilje B, D\u00e6hli Kurz K, Farbu E (2023) Impact of extent of resection on outcome from glioblastoma using the RANO resect group classification system: a retrospective, population-based cohort study. Neuro-Oncol Adv 5. https:\/\/doi.org\/10.1093\/noajnl\/vdad126","DOI":"10.1093\/noajnl\/vdad126"},{"key":"5481_CR29","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.wneu.2011.06.014","volume":"76","author":"S Gulati","year":"2011","unstructured":"Gulati S, Jakola AS, Nerland US, Weber C, Solheim O (2011) The risk of getting worse: surgically acquired deficits, Perioperative complications, and functional outcomes after Primary resection of glioblastoma. World Neurosurg 76:572\u2013579. https:\/\/doi.org\/10.1016\/j.wneu.2011.06.014","journal-title":"World Neurosurg"},{"key":"5481_CR30","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00701-019-04136-4","volume":"162","author":"J Dietterle","year":"2020","unstructured":"Dietterle J, Wende T, Wilhelmy F, Eisenl\u00f6ffel C, J\u00e4hne K, Taubenheim S, Arlt F, Meixensberger J (2020) The prognostic value of peri-operative neurological performance in glioblastoma patients. Acta Neurochir 162:417\u2013425. https:\/\/doi.org\/10.1007\/s00701-019-04136-4","journal-title":"Acta Neurochir"},{"key":"5481_CR31","doi-asserted-by":"publisher","unstructured":"Kasper J, Wende T, Fehrenbach MK, Wilhelmy F, J\u00e4hne K, Frydrychowicz C, Prasse G, Meixensberger J, Arlt F (2021) The prognostic value of NANO scale assessment in IDH-Wild-type glioblastoma patients. Front Oncol 11. https:\/\/doi.org\/10.3389\/fonc.2021.790458","DOI":"10.3389\/fonc.2021.790458"},{"key":"5481_CR32","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/neuros\/nyy098","volume":"84","author":"TH Ung","year":"2019","unstructured":"Ung TH, Ney DE, Damek D, Rusthoven CG, Youssef AS, Lillehei KO, Ormond DR (2019) The Neurologic Assessment in Neuro-Oncology (NANO) scale as an Assessment tool for survival in patients with Primary glioblastoma. Neurosurgery 84:687\u2013695. https:\/\/doi.org\/10.1093\/neuros\/nyy098","journal-title":"Neurosurgery"},{"key":"5481_CR33","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1227\/01.Neu.0000349763.42238.E9","volume":"65","author":"MJ McGirt","year":"2009","unstructured":"McGirt MJ, Mukherjee D, Chaichana KL, Than KD, Weingart JD, Quinones-Hinojosa A (2009) Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme. Neurosurgery 65:463\u2013470. https:\/\/doi.org\/10.1227\/01.Neu.0000349763.42238.E9","journal-title":"Neurosurgery"},{"key":"5481_CR34","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3988\/jcn.2018.14.3.393","volume":"14","author":"JH Phi","year":"2018","unstructured":"Phi JH, Lee SJ, Kang HS, Kim JE, Kim SK, Cho WS, Lee SY (2018) Postoperative transient neurologic dysfunction: a proposal for pathophysiology. J Clin Neurol 14:393\u2013400. https:\/\/doi.org\/10.3988\/jcn.2018.14.3.393","journal-title":"J Clin Neurol"},{"key":"5481_CR35","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1080\/09638288.2017.1423520","volume":"41","author":"MM Shannon","year":"2019","unstructured":"Shannon MM, Elf M, Churilov L, Olver J, Pert A, Bernhardt J (2019) Can the physical environment itself influence neurological patient activity? Disability Rehabil 41:1177\u20131189. https:\/\/doi.org\/10.1080\/09638288.2017.1423520","journal-title":"Disability Rehabil"},{"key":"5481_CR36","doi-asserted-by":"publisher","first-page":"4866","DOI":"10.1158\/1078-0432.CCR-23-3845","volume":"30","author":"YW Park","year":"2024","unstructured":"Park YW, Choi KS, Foltyn-Dumitru M, Brugnara G, Banan R, Kim S, Han K, Park JE, Kessler T, Bendszus M (2024) Incorporating supramaximal resection into survival stratification of IDH-wildtype glioblastoma: a refined multi-institutional recursive partitioning analysis. Clin Cancer Res 30:4866\u20134875","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05481-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05481-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05481-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T08:38:12Z","timestamp":1776069492000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05481-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["5481"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05481-y","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"19 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Data Protection Office at Oslo University Hospital and the South-Eastern Regional Ethical Committee (reference number: 21\/02197).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"PB has received grants from The Norwegian Cancer Society South\u2013Eastern Norway Regional Health Authority. He has received payment as a testimony expert from The Norwegian Expert Panel. He is member of the EANO guideline committee, and leader of The Norwegian Neuro-Oncology Group. EOVM has received grants from the Norwegian Cancer Society South-Eastern Norway Regional Health Authority, The Norwegian Brain Cancer Society, and The Norwegian Child Cancer Society. He has a leader role in the Norwegian Brain Tumor Consortium and the Scandinavian Society of Neurosurgery. EOVM has received payments for lectures from Brainlab AG, Germany and received travel reimbursements for lectures from Oxford Nanopore Technologies. LN has received grants from the Leukemia and Lymphoma Society and NIH\/NCI. She has revied Royalties from Wolters Kulwer, and consulting fees from Ono, Brave Bio, Genmab and Curis. LN has received payment for lectures from Ono and Astra Zenaca. She has participated in the data safety monitoring board in Kite\/Gilead, Ono, Miltenyi, and Curis. She has received clinical trail support from Merck, Astra Zeneca, Kazia, Ono and Curis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}